SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers-Reference-Cited by-同舟云学术

SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A inhibitor VX-680 in non-small cell lung cancers

Published:2017-01-19 Issue:1 Volume:8 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

Tagal Vural,Wei Shuguang,Zhang Wei,Brekken Rolf A.^ORCID,Posner Bruce A.,Peyton Michael,Girard Luc,Hwang TaeHyun,Wheeler David A.,Minna John D.,White Michael A.,Gazdar Adi F.,Roth Michael G.

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry

Link

http://www.nature.com/articles/ncomms14098.pdf

Reference64 articles.

1. Anguiano, A., Nevins, J. R. & Potti, A. Toward the individualization of lung cancer therapy. Cancer 113, 1760–1767 (2008).

2. Meric-Bernstam, F. & Mills, G. B. Overcoming implementation challenges of personalized cancer therapy. Nat. Rev. Clin. Oncol. 9, 542–548 (2012).

3. Garraway, L. A. Genomics-driven oncology: framework for an emerging paradigm. J. Clin. Oncol. 31, 1806–1814 (2013).

4. Larsen, J. E., Cascone, T., Gerber, D. E., Heymach, J. V. & Minna, J. D. Targeted therapies for lung cancer: clinical experience and novel agents. Cancer J. 17, 512–527 (2011).

5. Lynch, T. J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. New Engl. J. Med. 350, 2129–2139 (2004).

Cited by 87 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An update on small molecule compounds targeting synthetic lethality for cancer therapy;European Journal of Medicinal Chemistry;2024-11

2. Discovery of Novel, Potent and Orally Bioavailable SMARCA2 PROTACs with Synergistic Anti-tumor Activity in Combination with KRAS G12C Inhibitors;2024-08-26

3. Chromatin remodellers as therapeutic targets;Nature Reviews Drug Discovery;2024-07-16

4. SMARCA4 deficiency and mutations are frequent in large cell lung carcinoma and are prognostically significant;Pathology;2024-06

5. Successful treatment with tislelizumab plus chemotherapy for SMARCA4-deficient undifferentiated tumor: a case report;Frontiers in Immunology;2024-05-31